Table 2
Open in new tab

Reports containing more than 10 cases of combined hepatocellular-cholangiocarcinoma who received systemic treatment (adopted with modifications from reference [2].

AuthorCountryPublished year,
(Reference)		Included periodNumber of patientsSystemic treatmentORR (%)mPFS (months)mOS (months)
SaimonFrance2017, [35]2008 to 201730Gemcitabine+platinum28.69.016.2
KobayashiJapan2018, [36]2002 to 201536Gemcitabine+cisplatin,
fluorouracil+cisplatin,
sorafenib, others		5.62.88.9
TrikalinosUnited states
of America		2018, [37]1999 to 200668Gemcitabine +5-FU,
gemcitabine + platinum		0–24.34.8–8.09.6–11.7
KimSouth Korea2021, [38]1999 to 201599Sorafenib,
cytotoxic agents		14.13.810.6
GiganteFrance2022, [39]2009 to 202083Platinum,
molecular target agents,
others		13412
PomejEU2023, [40]2003 to 202244Cytotoxic agents, others6.83.0–3.24.6
JangSouth Korea2023, [41]2015 to 202125Immune checkpoint inhibitors20.03.58.3
GiganteFrance2023, [42]2020 to 202216Atezolizumab+bevacizumab33.3313
AuthorCountryPublished year,
(Reference)		Included periodNumber of patientsSystemic treatmentORR (%)mPFS (months)mOS (months)
SaimonFrance2017, [35]2008 to 201730Gemcitabine+platinum28.69.016.2
KobayashiJapan2018, [36]2002 to 201536Gemcitabine+cisplatin,
fluorouracil+cisplatin,
sorafenib, others		5.62.88.9
TrikalinosUnited states
of America		2018, [37]1999 to 200668Gemcitabine +5-FU,
gemcitabine + platinum		0–24.34.8–8.09.6–11.7
KimSouth Korea2021, [38]1999 to 201599Sorafenib,
cytotoxic agents		14.13.810.6
GiganteFrance2022, [39]2009 to 202083Platinum,
molecular target agents,
others		13412
PomejEU2023, [40]2003 to 202244Cytotoxic agents, others6.83.0–3.24.6
JangSouth Korea2023, [41]2015 to 202125Immune checkpoint inhibitors20.03.58.3
GiganteFrance2023, [42]2020 to 202216Atezolizumab+bevacizumab33.3313

ORR, objective response rate; PFS, progression-free survival; OS, overall survival

Table 2
Open in new tab

Reports containing more than 10 cases of combined hepatocellular-cholangiocarcinoma who received systemic treatment (adopted with modifications from reference [2].

AuthorCountryPublished year,
(Reference)		Included periodNumber of patientsSystemic treatmentORR (%)mPFS (months)mOS (months)
SaimonFrance2017, [35]2008 to 201730Gemcitabine+platinum28.69.016.2
KobayashiJapan2018, [36]2002 to 201536Gemcitabine+cisplatin,
fluorouracil+cisplatin,
sorafenib, others		5.62.88.9
TrikalinosUnited states
of America		2018, [37]1999 to 200668Gemcitabine +5-FU,
gemcitabine + platinum		0–24.34.8–8.09.6–11.7
KimSouth Korea2021, [38]1999 to 201599Sorafenib,
cytotoxic agents		14.13.810.6
GiganteFrance2022, [39]2009 to 202083Platinum,
molecular target agents,
others		13412
PomejEU2023, [40]2003 to 202244Cytotoxic agents, others6.83.0–3.24.6
JangSouth Korea2023, [41]2015 to 202125Immune checkpoint inhibitors20.03.58.3
GiganteFrance2023, [42]2020 to 202216Atezolizumab+bevacizumab33.3313
AuthorCountryPublished year,
(Reference)		Included periodNumber of patientsSystemic treatmentORR (%)mPFS (months)mOS (months)
SaimonFrance2017, [35]2008 to 201730Gemcitabine+platinum28.69.016.2
KobayashiJapan2018, [36]2002 to 201536Gemcitabine+cisplatin,
fluorouracil+cisplatin,
sorafenib, others		5.62.88.9
TrikalinosUnited states
of America		2018, [37]1999 to 200668Gemcitabine +5-FU,
gemcitabine + platinum		0–24.34.8–8.09.6–11.7
KimSouth Korea2021, [38]1999 to 201599Sorafenib,
cytotoxic agents		14.13.810.6
GiganteFrance2022, [39]2009 to 202083Platinum,
molecular target agents,
others		13412
PomejEU2023, [40]2003 to 202244Cytotoxic agents, others6.83.0–3.24.6
JangSouth Korea2023, [41]2015 to 202125Immune checkpoint inhibitors20.03.58.3
GiganteFrance2023, [42]2020 to 202216Atezolizumab+bevacizumab33.3313

ORR, objective response rate; PFS, progression-free survival; OS, overall survival

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close